A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer

This study has been completed.

First Received: May 17, 2002 Last Updated: November 12, 2009 History of Changes

Sponsor:	Amgen
Information provided by:	Amgen
ClinicalTrials.gov Identifier:	NCT00037518

Purpose

This study will assess an investigational medication for patients with severe primary hyperparathyroidism or parathyroid cancer.

Condition	Intervention	Phase
Hyperparathyroidism Parathyroid Neoplasms	Drug: AMG 073	Phase IV

Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	An Assessment of the Calcimimetic Agent AMG 073 for the Treatment of Subjects With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism.

Resource links provided by NLM:

MedlinePlus related topics: Cancer

Drug Information available for: Cinacalcet Cinacalcet hydrochloride Parathyroid

Further study details as provided by Amgen:

Primary Outcome Measures:

Secondary Outcome Measures:

Estimated Enrollment:	46
Study Start Date:	April 2001

Eligibility

Criteria

Patients must have parathyroid carcinoma or severe primary hyperparathyroidism; * Abnormally elevated calcium levels above 12.5 mg/dL; * Not be pregnant or nursing; * Not have had any type of cancer other than parathyroid carcinoma within the last 5 years.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00037518

Sponsors and Collaborators

Amgen

Investigators

Study Director:

Amgen

More Information

Additional Information:

AmgenTrials clinical trials website This link exits the ClinicalTrials.gov site

Publications:

Responsible Party:	Amgen Inc. ( Global Development Leader )
Study ID Numbers:	20000204
Study First Received:	May 17, 2002
Last Updated:	November 12, 2009
ClinicalTrials.gov Identifier:	NCT00037518 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Amgen:

Severe primary hyperparathyroidism
Parathyroid carcinoma

Additional relevant MeSH terms:

Parathyroid Diseases
Parathyroid Neoplasms
Neoplasms
Neoplasms by Site
Hyperparathyroidism

Head and Neck Neoplasms
Endocrine System Diseases
Hyperparathyroidism, Primary
Endocrine Gland Neoplasms

ClinicalTrials.gov processed this record on March 18, 2010